Compare Axogen Inc (AXGN) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Axogen Inc vs Synopsys, Inc. — how do they compare? Axogen Inc trades at $38.39 (market cap $2.06B), while Synopsys, Inc. trades at $429.36 (market cap $81.55B). The key difference: Synopsys, Inc. is far larger — about 39.6× Axogen Inc's market cap, and Axogen Inc is trading nearer its 52-week high, Synopsys, Inc. nearer its low. Which is the better fit depends on your goals.
| AXGN | SNPS | |
|---|---|---|
Market Cap | $2.06B | $81.55B |
Sector | Technology | Technology |
52-Week High | $46.19 | $645.59 |
52-Week Low | $11.28 | $380.47 |
Enterprise Value | $1.98B | $89.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $39.49, down 2.69% today, with a bearish technical signal despite recent earnings volatility. The company reported mixed quarterly results with Q3 2025 beating estimates but Q1 2026 missing expectations. Strong analyst sentiment persists with 84% buy ratings and a $47.60 consensus price target, though negative profit margins and recent technical weakness create uncertainty.
The outlook remains cautiously optimistic given strong institutional support and reimbursement progress, but investors face risks from persistent losses and competitive pressures. The stock's current position near support at $39 suggests potential for recovery if upcoming Q2 earnings meet or exceed the $0.09 EPS estimate.
Synopsys (SNPS) trades at $433.82, down 2.6% today, with a bearish technical signal from moving averages but oversold short-term RSI at 29.08. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $3.35 surpassing the $3.15 estimate. Revenue grew to $7.05B in 2025, though net income margin compressed to 8.91%. Valuation multiples remain elevated with a P/E of 99.27 and P/S of 9.16. Recent news highlights Synopsys' strategic pivot toward AI-driven design tools and multiphysics solutions.
Outlook: Analyst consensus is bullish with an average price target of $558.33, implying 29% upside, supported by 24 buy ratings. Risks include integration challenges from the Ansys acquisition, competitive pressures in EDA software, and volatility in semiconductor capex. The stock's high valuation requires sustained execution on AI-related growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Axogen Inc
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
